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Abstract
Background: The tropomodulins (TMODs) are a family of proteins that cap the pointed ends of
actin filaments. Four TMODs have been identified in humans, with orthologs in mice. Mutations in
actin or actin-binding proteins have been found to cause several human diseases, ranging from
hypertrophic cardiomyopathy to immunodefiencies such as Wiskott-Aldrich syndrome. We had
previously mapped Tropomodulin 2 (TMOD2) to the genomic region containing the gene for
amyotrophic lateral sclerosis 5 (ALS5). We determined the genomic structure of Tmod2 in order
to better analyze patient DNA for mutations; we also determined the genomic structure of
Tropomodulin 4 (TMOD4).
Results: In this study, we determined the genomic structure of TMOD2 and TMOD4 and found the
organization of both genes to be similar. Sequence analysis of TMOD2 revealed no mutations or
polymorphisms in ALS5 patients or controls. Interestingly, we discovered that another gene, YL-1,
intergenically splices into TMOD4. YL-1 encodes six exons, the last of which is 291 bp from a 5'
untranslated exon of TMOD4. We used 5' RACE and RT-PCR from TMOD4 to identify several
intergenic RACE products. YL-1 was also found to undergo unconventional splicing using non-
canonical splice sites within exons (intraexonic splicing) to produce several alternative transcripts.
Conclusions: The genomic structure of TMOD2 and TMOD4 have been delineated. This should
facilitate future mutational analysis of these genes. In addition, intergenic splicing at TMOD4/YL-1
was discovered, demonstrating yet another level of complexity of gene organization and regulation.
Background
Tropomodulins are the vertebrate proteins that cap the
pointed ends of filamentous actin [1]. The first tropo-
modulin (TMOD) gene was cloned by Sung and col-
leagues (1992) from a fetal liver library. Three additional
family members have been identified in humans, and
TMOD homologs have been identified in mouse, rat,
chick, Drosophila, and C. elegans [2–8]. Expression pat-
terns vary extensively: Tropomodulin 3 (TMOD3) is
ubiquitous; Tropomodulin 1 (TMOD1) is widespread in
heart, muscle, brain, lens, erythrocytes, and arterioles;
Tropomodulin 2 (TMOD2) is restricted to neuronal tis-
sue; Tropomodulin 4 (TMOD4). is expressed in skeletal
muscle, with a less abundant ~7 kb transcript expressed
in both skeletal and cardiac muscle [8]. Whereas tropo-
modulins or the Arp 2/3 complex cap the pointed end of
actin filaments, the barbed end can be capped by CapZ,
α , β , and γ  adducins as well as gelsolin [9–11]. Control of
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thin filament length is critical for maintaining proper
sarcomere function and length[12]. Inhibition of
Tmod1's capping activity – either by using an antibody to
its C-terminal end or by decreasing expression using an
antisense Tmod1 transcript – results in elongated thin
filaments and decreased cardiac contractility [13,14].
Tmod1 overexpression in rat cardiomyocytes causes
shortening of the thin filaments and sarcomere disor-
ganization, resulting in myofibril degeneration [14].
Likewise, mice overexpressing TMOD1 in the heart show
disrupted sarcomere organization with shortened thin
filaments, leading to myofibril degeneration and dilated
cardiomyopathy [15]. Recently, Littlefield and colleagues
showed that overexpression of GFP-Tmod1 in chick car-
diac myocytes results in shortening of thin filaments; the
authors proposed that excess Tmod1 decreases the affin-
ity between actin monomers and pointed ends, leading to
monomer dissociation and filament shortening [42].
Mutations in many proteins making up the cardiac sar-
comere have been shown to cause cardiac hypertrophy
[16–19]:mutations in the TPM1 gene, for example, cause
type 3 familial hypertrophic cardiomyopathy (CMH3),
and a transgenic mouse expressing a CMH3 mutation
develops ventricular myocyte disarray and hypertrophy
[20]. Mutations in myosin heavy chain 7 are estimated to
account for 40–50% of the cases of hypertrophic cardio-
myopathy [21].
Given the importance of actin-binding proteins in hu-
man disease, we mapped TMOD2 and TMOD4 and
found them to localize to 15q21.1 and 1q12, respectively
[8]. These loci overlap with the genomic regions contain-
ing the genes for amyotrophic lateral sclerosis 5 (ALS5)
and limb girdle muscular dystrophy 1B (LGMD1B), re-
spectively [22,23]. We characterized these tropomodulin
genomic loci for use in mutational analysis. During the
course of this study, the gene mutated in LGMD1B was
identified as Lamin A/C [24]. Our investigation, howev-
er, revealed that an unrelated gene, YL-1, intergenically
spliced into TMOD4 . YL-1 is a putative transformation
suppressor gene that localizes to the nucleus and binds to
DNA [25,26]. YL-1 is organized into six exons and pro-
duces several alternatively spliced transcripts using both
intergenic and cryptic splicing. This relationship be-
tween YL-1 and TMOD4 serves as yet another example of
the complexity of genomic organization and gene regula-
tion.
Results
Genomic organization of TMOD2, TMOD4, and YL-1
We determined the exon/intron boundaries of TMOD2
and  TMOD4 by sequencing PCR products amplified
from primers within adjacent exons, and sequencing
short exon containing genomic fragments. We identified
nine coding exons in TMOD2 and in TMOD4 which are
spread over a 45 kb and 4.7 kb genomic region, respec-
tively (Fig. 1). The exon/intron boundaries of the two
genes are conserved, except that TMOD2 has more 5' un-
translated region (UTR) in coding exon 1 and more 3'
UTR in exon 9 than TMOD4. TMOD2 and TMOD4 also
contain additional 5' UTR exons. Our reported cDNAs
have 69 and 19 bp additional sequence 5' to what is con-
tained in exon 1 for each gene, respectively [8]. A search
of the EST database using the TMOD4 5' end extended
this sequence by 8 bp (ESTs AA194560, AA192772, and
AA178988). We were able to align this sequence and
found that it lies 1006 bp from TMOD4 exon 1 and con-
tained a consensus donor splice site. Using 5' rapid am-
plification of cDNA ends (RACE) from TMOD4 exon 2,
we discovered that this exon was 93 bp in length and con-
tained no consensus AG acceptor. 3' RACE from TMOD4
exon 2 extended our reported cDNA by an additional 9
bp, bringing the entire length of the TMOD4 transcript to
1.267 kb (Genbank Accession# AF393374).
Using the 5' end of the TMOD2 cDNA, we searched the
high throughput genomic sequences (HTGS) database
and identified a sequence, NT 010204, that contained
100% identity to the 69 basepairs of TMOD2 5' UTR and
contained a consensus GT donor splice site. The distance
from this UTR exon to coding exon 1 is 14.6 kb, but the
sequence is not completely ordered. Using nomenclature
from previous tropomodulin genes we designated these
5' UTR exons as E0 [27].
We sought to determine the genomic structure of YL-1
when we discovered that it lies next to and intergenically
splices into TMOD4 (see below). Using the same meth-
ods described above, we identified six coding exons of
Figure 1
Genomic structure of TMOD2, TMOD4, and YL-1. Numbered
rectangles represent coding exons, E0 represents 5' UTR
exons. ATG represents the start codon of each gene and
TAA or TAG represent the termination codon of each gene.
Scale below is in kilobases (kb).
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Table 1: 
TMOD2
Exon 5' intron (5'-3) Exon (bp) 3' intron (5'-3') Intron (kb)
E0 5' UTR 69 GTGAGCGCCCCGGGGGGCGGGTGG 14.6
1 TATTGTGTTTCTTTTTTATTAACAG 195 GTTAGTGACATGGAACTGAAGCAGA 1.7
2 CCTGCTCACACCTCTTTCTTGTCAG 157 GTAAGGACCACAGGCAGAGCATCTT 5
3 TTTTTGTTTTTCTTCTGATTTAAAG 123 GTTAGTCCTGAACTCTGGGAACTTT 3
4 ATGCTCATTTGTTGACTGTTTTTAG 87 GTAAGTTGATGTGCAATCTGTGGTT 3.6
5 TTTAAAATGAAAACTTGTGTTTTAG 131 GTATTTCATTGTGATTATCATCAGT 1.6
6 ACTAGCCATGTCCTCTCTGTCTTAG 108 GTGAGTAAAATTCTTAGAAATATAA 17
7 GTTTTTTTTCTTTTTGCATCATAAG 144 GTAAGGAAGGCCAGAGAATAGGCAA 8
8 TGCATGTGTCTGCACCTGCAACCAG 145 GTAATTCAGCCATAATATTTGCTGT 2
9 TTTTGTTCCTTTCTTTCTTACCTAG 1314 3' UTR
TMOD4
Exon 5' intron (5'-3') Exon (bp) 3' intron (5'-3') Intron (bp)
E0 5' UTR 93 GTAGGTGGGGAAGACAGGGGGCTTA 1006
1 CATCCTTTTGTCCCATGTTGCCCAG 165 GTAGGGGCTCCAGCACAGGGAACCA 205
2 TTGCTCCCCAAAACTCATCCCTAAG 157 GTATGGGGACCCTGACATCCATGCC 775
3 GAGCCATCCTTCATCTCCCCATCAG 117 GTGGGTAGCTGTGGGAAGTTGAGGG 952
4 TGACTCCTCTTCTTACCCTCTCCAG 90 GTGAGTGTGTTTGGGGAGCATGGTC 506
5 TTCCCTTCCTGCCCTCATTCACCAG 131 GTATTTGACTTGCATCCTCCAAACC 92
6 ACCATCTCCTATTCCCCTCCGATAG 108 GTAAGGCTAGTTGACATCCCCAGCC 368
7 CCTAACCCAAGTCCCTACTACCCAG 144 GTCAGCATTCCCTTCCCCTGATGTT 256
8 CAGCTTTTGCCTCTCCCTCCCCCAG 145 GTGAGTAACTGCAGACATGATGTGT 415
9 TATGTTTAATATTGCTCCTTTACAG 108 3' UTR
YL-1
Exon 5' intron (5'-3') Exon (bp) 3' intron (5'-3') Intron (kb)
1 5' UTR 122 GCAAGATCCGGGCCTGGGAAAAGGG 4.5
2 AACCCTTATCTCCCTGTGTCCTTAG 153 GTACAGGGGGAGTCCTAGTTGTCTT 0.178
3 GTATCTGATTCCAATCTGTCCTCAG 115 GTGAGTAGGGATGTTAGGGTCAATT 1
4 TTCTTCTTATCTCACTCTCTTCCAG 177 GTAAGTCTGTGGTTTCAGAAAAAGT 6
5 CTCATTTCTTCCTTTGACCCTAAAG 145 GTGAGTGAATCTCAAGAGGAAAAGA 1.2
6 GTTTTTCCTTGTCTTTTGTCCTCAG 724 3' UTRBMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
YL-1 spanning 14.2 kb (Fig. 1). The distance from the last
exon of YL-1 to E0 TMOD4 is 291 bp. We sequenced the
entire genomic region encompassing TMOD4 from the
end of YL-1 exon 6 through TMOD4 exon 9 and deposit-
ed it in Genbank (Accession No. AF393375). The sizes of
the exons and introns as well as the boundary sequences
for TMOD2, TMOD4, and YL-1 are provided (See Table
1). Consensus splice sites were identified for all Tropo-
modulin exons, but YL-1 exon 1 contained a GC 5' splice
site instead of the more common GT 5' splice site. This
splice site also conforms well to other nonconsensus GC
5' splice sites as described in Mount (2000) with a G at
the -1 and +5 positions [28]. We used the very 3' end of
the YL-1 cDNA to look for additional 3' UTR. We identi-
fied three ESTs (ESTs AA128103, AW627363, and
AI591193) that were identical at the 3' end and extended
the reported UTR by an additional 150 bp.
Mutational Analysis of TMOD2 in ALS5
Two patients and two controls from a family with an au-
tosomal recessive form of familial ALS (ALS5) were ana-
lyzed for mutations in TMOD2. We amplified coding
exons 1–9 using primers flanking each exon (See Table
2). These PCR products were sequenced to identify any
potential point mutations or small deletions. We did not
detect any mutations or polymorphisms in any of the pa-
tients or controls.
Inter genic splicing of YL-1 into TMOD4
During our analysis of TMOD4's genomic structure we
identified EST AI763406, which contains TMOD4 exon 9
and part of the coding region of another unrelated gene
known as YL-1. Using 5' RACE we were able to confirm
the presence of this transcript and identify other unique
intergenic RACE products. Figure 2 summarizes our
findings. There are two main intergenic products, each of
which was represented multiple times in our RACE
clones. The first intergenic splice products (RACE #9–11,
and 13–15) are similar to EST AI763406. These variants
consist of YL-1 exons 1–5, and TMOD4 exon 9. The ORF
of this splice variant keeps the reading frame of YL-1 but
changes the TMOD4 endogenous reading frame to make
the reading frame of exon 9 completely open. Transla-
tion of this ORF would theoretically produce a protein of
at least 271 amino acids containing the amino terminal
half of YL-1 but a unique carboxy terminus. If, however,
we extend the sequence to include intronic sequence
downstream of exon 9, we discover that the frame is kept
open an additional 45 bp, making this theoretical protein
286 amino acids in length. Using primers to exon 1 of YL-
1 and exon 9 of TMOD4, we confirmed the presence of
this intergenic product by RT-PCR on human heart RNA.
RACE product #12 was similar to RACE products #9–11,
13–15 except that YL-1 splices from exon 5 to TMOD4
exon 8 which then splices to exon 9 (Fig. 2). This produc-
es an ORF coding for a 252 amino acid protein that
changes the frame of TMOD4, adding only 16 additional
amino acids before encountering a stop codon. Another
set of RACE products (RACE # 1–5) consists of YL-1 ex-
ons 4 and 5 and TMOD4 exons 1–9, except that exon 2
uses an internal consensus cryptic splice site. Using the
YL-1 endogenous frame we find that this ORF terminates
in TMOD4 exon 1. If we assume an ORF including YL-1
exons 1–3 along with the isolated RACE product, then it
Table 2: 
TMOD2
Anneal
Exon (° C) Forward Primer (5'-3') Reverse Primer (5'-3') Product size (bp)
1 54 TTCAATACAGTAGGCTCCA CGAGCTAAGGGATTTCTAC 393
2 55 GGTATCCTTCCTGCTTCC GGCTTATTTCCCATGTCT 413
3 54 TCTGCTCAGTCTACTTACCC CCATAATGCCTTGTGTCA 322
4 54 TTCAAGGGACAAATTAACA AAAGCCCAAGTGATCCTA 289
5 54 AGTGTTATTGGAATCAGCAT CTCCAACTCAGTGACTACAAA 358
*GTAAAACGACGGCCAGTTGCTGAAGGCTA **GGAAACAGCTATGACCATGACTATAAT
6 57 GGTAATGA TTTGCTCACTAACTGT 390
7 54 TTAATTTGGGAGTGAGGG ACAGGAAATCCAGTACATCA 356
8 54 CCTGTGCAAGTAACTGTTTC AGTGACATCAGAGGCCAG 323
9 54 ATGTTGTTTATCTGGAATTTA CCCATGAGCAAATAAAAC 307
*indicates a M13 universal sequence attached **indicates a M13 reverse sequence
at 5' end attached at 5' endBMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
would theoretically produce a protein of 264 amino ac-
ids. We used the translated protein sequences from these
intergenic ORFs and analyzed them using InterPro Scan
via EXPASY. No additional sequence motifs or domains
were identified. Another type of RACE product we iden-
tified (RACE# 26–31) is the incompletely spliced prod-
ucts of TMOD4. In no case did we observe the inclusion
of YL-1 exon 6 or the use of the normal splice acceptor of
TMOD4 exon 2 – the cryptic splice acceptor was always
present in intergenic RACE products. Furthermore, the
YL-1 alpha helical domain, which is thought to contain
the DNA binding domain, is maintained in all intergenic
splice products contained within YL-1 exons 4 and 5.
YL-1 intraexonic spliced transcripts and expression pattern
To better understand the nature of YL-1's intergenic
splicing, we searched the EST database for other alterna-
tive and intergenic YL-1 transcripts. Using either the YL-
1 or TMOD4 cDNAs in a BLAST search of the human EST
database, we were unable to identify any additional
intergenic transcripts, but we did uncover several YL-1
ESTs that had apparently spliced within exons in such a
way as to not use the canonical consensus splice accep-
Figure 2
Summary of RACE products: Hatched rectangles represent YL-1 exons. Diagonal striped rectangles represent TMOD4 exons.
Numbers in parentheses represent the number of amino acids produced from each ORF. Black rectangles represent introns,
and horizontally striped rectangles represent exons which used a cryptic splice site.BMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
tors or donors, the rarer GC or AT donor sites or the AC
acceptor site[29]. ESTs AI560960 and AI369608 were
identical and contained YL-1 exons 1 and 2 but splice
within exon 2 at position 276 (position is in bp relative to
Genbank sequence D43642) to position 1107 (internal to
exon 6) (Fig. 3). Translation of this ORF would produce
a truncated protein of only 121 amino acids. EST
AI560960 was obtained from the IMAGE consortium
and sequenced. It is 476 bp in length and contains YL-1
exons 1 and up to position 276 in exon 2 at which it splic-
es internal to exon 6 at position 1107. A second splice
product was represented by ESTs AI366716 and
AW005187, in which the sequence appears to splice from
position 113 in exon 1 to exon 6 at position 936 (Fig. 3).
This would produce another truncated protein that is 89
amino acids in length. Another unusual splice product
was represented by ESTs AA443950 and AA653180.
These ESTs demonstrate splicing within YL-1 exon six it-
self, from position 936 to 1062 (skipping over ~126 bp),
changing the frame and making it open past the endog-
enous stop codon (Fig. 3). EST AA443950 was obtained
from the image consortium and sequenced. It contained
a 1199 bp insert which contained all of YL-1 exons 1–5
and exon six as described above and encodes an ORF for
a 358 amino acid protein. However, EST AA653180 has
an additional six base pairs at the splice junction site
coding for leucine and proline, suggesting that either the
site produces two different splice variants or there is
some type of intermediate stage of splicing at this site. In
either case, the protein produced from this ORF (if
AA653180 contains the rest of the intact 5' YL-1 tran-
script) would be 360 amino acids. This truncates the re-
ported YL-1 protein only by 6 or 4 amino acids. Using
InterPro Scan via EXPASY, we determined that these few
amino acids do not produce any potential phosphoryla-
tion sites or protein domains or motifs. Two of these
three splice variants use the 936 position for splicing as
a putative donor in one case and as an acceptor in the
other. We cannot explain this finding, but it may suggest
that YL-1 undergoes a great degree of intraexonic splic-
ing. This high degree of splicing together with the lack of
a GT donor site in the last exon, and the close proximity
of YL-1 and TMOD4, may account for the intergenic
splicing between these genes.
We also wanted to determine whether the YL-1 expres-
sion pattern overlapped with TMOD4. A human multiple
tissue Northern blot was probed with a YL-1 RT-PCR
product revealing a single 1.4–1.6 kb band in all lanes
(Fig. 4). This is consistent with the reported ubiquitous
expression of YL-1 in the rat [25].
Discussion
Sequencing PCR fragments and genomic subclones from
phage artificial chromosomes (PACs) and bacterial arti-
ficial chromosomes (BACs) that contain TMOD2 and
TMOD4 allowed us to determine the genomic structure
of these two Tropomodulin genes. Although mutational
analysis of the coding region of TMOD2 in ALS5 and
TMOD4 in LGMD1B patients failed to reveal any point
mutations, small deletions, or polymorphisms, we did
find that TMOD2 and TMOD4 consist of nine coding ex-
ons and at least one 5' untranslated exon (E0).
Figure 3
Hatched rectangles represent YL-1 exons. Thick black lines
represent the intraexonic splice events. The number of
amino acids produced by each ORF is in parentheses.
Asteriks represent the positions of intraexonic non-canonical
splice sites used in multiple ESTs.
Figure 4
Human multiple tissue Northern blot probed with YL-1 RT-
PCR product revealed a single highly expressed transcript
between 1.4–1.6 kb in all tissues.BMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
This is identical to the genomic structure reported for
TMOD1 and Tmod1 by Chu and colleagues and Conley et
al. [27,41]. In addition, they identified an 86 bp 5' UTR
exon which was expressed in a tissue-specific manner.
We performed 5' RACE for TMOD4 and identified only a
single 93 bp 5' UTR exon (E0) which lies 1006 bp from
coding exon 1. We did not examine whether the E0 exons
of TMOD2 and TMOD4 were expressed in a tissue-spe-
cific manner. In addition, the TMOD2 transcript is ap-
proximately 9.5–10 kb in length and our reported cDNA
only accounts for 2.47 kb [8]. Therefore, there are addi-
tional UTR exons or sequence that we have not identified
in this study. This may not be the case for TMOD4, be-
cause our reported cDNA in addition to the 93 base pairs
from the E0 sequence and the additional 9 bp from the 3'
end produces a transcript of the same size as the major
transcript seen by Northern. However, the larger tran-
scripts (2.4 and 3.0 kb) seen on Northern may contain
additional sequence that we were unable to identify in
this study, or may represent incompletely spliced tran-
scripts.
EST database searches in conjunction with the YL-1 ge-
nomic structure allowed us to identify three unique in-
traexonic splicing events. Two of the three events
theoretically would produce truncated proteins with lit-
tle similarity to the normal protein. These splicing events
do not use the canonical AG and GT splice sites, nor do
they use the rarer GC, AT, or AC splice sites. This may
represent yet another form of splicing for the creation of
unique transcripts and, or gene regulation.
We also identified two intergenic transcripts between
YL-1 and TMOD4, both of which theoretically would
code for truncated versions of YL-1. Intergenic splicing
appears to be a rare event: apparently there have been
only six other cases reported in mammals. Fears et. al
(1996) reported that the Myelodysplasia syndrome
1(MDS1) gene spliced into exon 2 of the adjacent Eco-
tropic viral integration site 1 (EVI1) gene, producing a
unique transcript containing an ORF that produces a
GATA-binding transcriptional activator [30,31]. The hu-
man Galactose-1-phosphate uridylytransferase (GALT)
gene produces an intergenic transcript by skipping its
last exon and splicing into exon 2 of Interleukin-11 re-
ceptor α -chain (IL-11Rα ) [32]. This produces an inter-
genic transcript that keeps the endogenous frame of both
genes, thereby coding for a theoretical protein with do-
mains from both proteins. A long terminal repeat from a
human endogenous retrovirus (HERV) was shown to
drive the expression of an intergenic transcript from an
unknown gene named HERV-HLTR associating 1
(HHLA1) and human otoconin-90 (OC90) to produce a
transcript that is highly expressed in teratocarcinoma
cells but not in normal human tissues or cell lines [33].
In the mouse, a Prion-like downstream gene named dop-
pel (Dpl) was found to have an intergenic transcript that
is upregulated in Prion-deficient mice [34]. The deletion
of the Prion gene in these mice removes the splice accep-
tor site of exon 3, causing the normal Prion transcript to
skip the deleted exon and inadvertently upregulate the
normally low-abundance intergenic transcript by forcing
it to splice more often to the doppel gene. The human cy-
tochrome P450 2C gene cluster maps to chromosome
10q24 and consists of four genes which are composed of
nine exons with conserved exon/intron boundaries, and
have been shown to produce intergenic transcripts [35–
38]. These transcripts have been identified by RT-PCR
for both neighboring genes such as CYP2C18 and
CYP2C19, as well as CYP2C members separated by an-
other gene, such as CYP2C18 and CYP2C8 [37,38]. The
latter was shown by RT-PCR to include exons from both
genes consisting of nine exons and therefore could code
for a chimeric CYP2C protein [38]. Recently, the Trans-
lin-associated factor X gene (TRAX) was demonstrated
to intergenically splice into Disrupted in schizophrenia
gene 1 (DISCI) [39]. Several intergenic transcripts were
described, the majority of which contain intervening
non-coding exons that contain multiple stop codons.
At least half of the reported cases of intergenic splicing
result from skipping the last exon of the upstream gene
and the first exon of the downstream gene [32,33,39].
This is thought to be due to the lack of donor and accep-
tor splice sites in these exons, respectively. For YL-1 exon
6 there is no GT donor site at the end of the exon, and the
E0 exon of TMOD4 contains no AG acceptor. Thus the
same pattern seen in the other reported intergenic splic-
ing events is born out in our studies. This idea is support-
ed by the fact that we never identified any part of the E0
exon in our RACE products screened using the YL-1 cD-
NA. However, we did discover this product when we re-
screened our RACE products using a 5' TMOD4 probe.
Of the previously reported cases, the closest distance be-
tween adjacent genes is 4 kb [32]. YL-1 and TMOD4 are
separated by 291 bp. Since this genomic region is so
small, it raises the question as to the location of the
TMOD4 promoter. One possibility is that it lies within
the 1006 bp between the E0 exon and coding exon 1, or
even within the 291 bp between the E0 exon and YL-1
exon 6. A more intriguing possibility is that the TMOD4
promoter lies further upstream, possibly within the in-
tronic structure of YL-1, or as a shared promoter with YL-
1.
Whether these intergenic splice products are biologically
relevant is unclear. Due to the fact that the size of the
transcripts for TMOD4 and YL-1 overlap (1.3 – 1.5 kb),
we cannot demonstrate the co-existence of these inter-
genic variants by Northern blot analysis. The only re-BMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
ported case in which an intergenic transcript has been
shown to produce a functional protein in vivo is the case
of MDS1/EVI1[31]. In all other cases, the intergenic tran-
script or the theoretical protein produced from such
transcripts has been difficult to demonstrate by North-
ern blot analysis, and none have been shown by Western
analysis in normal tissues. However, all of these tran-
scripts have been identified by RT-PCR and some by
RNase protection assays. Thus, further analysis will be
needed to determine if any of the YL-1/TMOD4 intergen-
ic transcripts play an important biological role either at
the RNA or protein levels.
Conclusion
Through our genomic analysis we were able to determine
that  TMOD2 and 4, like TMOD1/Tmod1, share con-
served genomic structures consisting of nine coding ex-
ons and a single 5' UTR exon (E0). Using primers
flanking the coding exons of TMOD2 we performed mu-
tational analysis on ALS5 patients. No mutations or pol-
ymorphisms were detected, but our primer pairs and
reaction conditions may prove useful for future muta-
tional analyses. We determined that YL-1 comprises six
exons, and its last exon lies 291 bp from TMOD4. We also
identified six ESTs that show nonconventional splicing.
Intergenic splice products between YL-1 and TMOD4
were identified in the EST database, by 5' RACE, and by
RT-PCR. Although we did not determine whether this re-
lationship between YL-1 and TMOD4 is conserved in the
mouse, it may be an important possibility to consider
when devising strategies for targeted deletion not only of
YL-1 or TMOD4 but any gene pair in which intergenic
splicing occurs. This is clearly illustrated by the Prion de-
ficient mice produced by Sakaguchi et. al (1996) and
Moore (1997). In these animals exon 3 and its splice ac-
ceptor were deleted, causing a rare intergenic transcript
between Prion and Doppel to be highly upregulated and
abnormally expressed in the brain, leading to late-onset
ataxia and Purkinje cell degeneration[34].
The recent completion of the human genome by Ventner
et. al (2001) has led to the new prediction that the human
genome contains only ~30,000 genes, significantly low-
er than previous estimates of ~100,000 genes [40]. This
estimate does not, however, include the possibility of ad-
ditional proteins encoded by alternative or intergenic
transcripts. The genomic organization between YL-1 and
TMOD4 clearly raises the possibility of additional pro-
teins being produced from intergenic transcripts. In ad-
dition, it highlights the difficulties that may arise when
trying to understand gene regulation for genes that lie
extremely close to one another or that form intergenic
transcripts. YL-1's intraexonic splicing illustrates yet an-
other level of genomic complexity in that alternative
transcripts could be produced from the use of non-ca-
nonical splice sites that lie even within an individual ex-
on. This, in conjunction with intergenic splicing, may
significantly increase the number of predicted proteins
encoded by the human genome and will certainly pose a
challenge for anyone trying to decipher genomic organi-
zation and regulation.
Materials and Methods
Genomic organization and sequence analysis of TMOD2, 
TMOD4, and YL-1
The genomic organization of each gene was determined
using two methods. The first involved PCR amplification
from either PAC 61J10 (for TMOD2) or BAC HB342I3
(for TMOD4 and YL-1) using primers within each exon to
amplify the exon and the intervening intron and use it as
a substrate for sequencing the exon-intron boundaries.
We also digested PAC 61J10 (from the RPCI-1 human
PAC library, Roswell Park Cancer Institute) and BAC
HB342I3 (from the human CITB BAC library. Research
Genetics, Inc.) with RSAI and then subcloned the DNA
fragments into pZero 2.0 according to the manufactur-
er's instructions. We screened colonies by hybridization
using the cDNA for each gene as a probe. All labeling re-
actions for all procedures were performed using the
Megaprime DNA labeling system (Amersham Pharmacia
Biotech, Piscataway, NJ). Positive colonies were isolated
and sequenced using a PRISM BigDye Terminator Cycle
sequencing kit and an ABI 3700 automated DNA se-
quencer (Perkin-Elmer Applied Biosystems, Foster City,
CA).
Mutational Analysis of TMOD2 for ALS5 and TMOD4 for 
LGMD1B
The coding exons of TMOD2 and TMOD4 were amplified
from patient lymphoblast genomic DNA using primers
flanking the exon (Table 2). Reaction conditions were as
follows for a 50 µl PCR reaction : Perkin-Elmer Cetus
PCR buffer; 1.5 mM MgCl2, 0.25 mM dNTPs, 1.5 µl of
each primer (10 µM), 1% DMSO, 5 U of Taq polymerase
(Life Technologies). Thermocycler conditions were as
follows for a Perkin Elmer 9600 thermocycler: 94°C for
4 min, followed by 35 cycles of 94°C for 30 s, annealing
temperature (see Table 2) for 30 s, 72°C for 1 min, and a
final extension of 72°C for 10 min. The resulting PCR
products were subjected to agarose gel electrophoresis
and the DNA was recovered from excised bands using the
Qiagen Quick Gel Extraction Kit (CAT# 28706). Each
PCR product was then sequenced.
5' and 3' Rapid Amplification of cDNA ends for TMOD4
We used Clontech's Human Heart Marathon-Ready
cDNA (Cat # 7404–1) to perform 5' and 3' RACE to the
TMOD4 gene. Nested primers were designed within
exon 9 and exon 2 of TMOD4, TMOD4EX9RACE5'.1
5'TACAGGAAAGGAGGACAGATGAGG3', and TMOD4EBMC Genomics 2001, 2:7 http://www.biomedcentral.com/1471-2164/2/7
X9RACE5'.2 5'GATTTAAGTGTCCAGTGCTCCCAG3',
and TMOD4EX2RACE5'.1  5'GGGCACCAAGTCATCAC
GCTCT3', TMOD4EX2RACE5'.2 5'CCAAGTACTGCAA
AAGGGCCTC3', TMOD4EX2RACE3'.1  5'GGACTAAGA
CAACGTGACCAGACA3', and TMOD4EX2RACE3'.2
5'GAGGCCCTTTTGCAGTACTTGG3'. The initial RACE
reaction to identify intergenic RACE products was per-
formed using the gene specific primer,
TMOD4RACE5'.1, and Clontech's AP1 primer in a 50 µl
reaction using the Roche High Fidelity Kit (CAT# 1–
732–641). Thermocycler conditions for a PE9600 were
as follows: 94°C for 5 min, followed by 10 cycles of 94°C
for 30 s, 71°C for 30 s, 72°C for 4 min; followed by one cy-
cle of 94°C for 30 s, 68°C for 4 min 20 s, followed by 17
additional cycles each adding 20 s to each extension; fi-
nal extension at 72°C for 10 min. 5 µl of a 1:50 dilution of
the product from the first RACE reaction served as tem-
plate for the second nested RACE reaction. Reaction and
thermocycler conditions were the same as before except
gene specific primer 2, TMOD4RACE5'.2, and Clontech's
AP2 primer were used. RACE products were then sub-
cloned into pbluescript KS II+ using TA vector cloning.
Positive products were then identified by colony hybrid-
ization using the YL-1 cDNA as a probe. A secondary
screening was then performed using exon 2 primers
TMOD4EX2RACE5'.1, followed by a second round of
race using TMOD4EX2RACE5'.2. Likewise the 3' RACE
was performed using TMOD4EX2RACE3'.1, followed by
TMOD4EX2RACE3'.2. RACE products were then sub-
cloned and identified by using either a 5' or 3' probes
made from the TMOD4 cDNA. Positive RACE products
were sequenced.
RT-PCR of YL-1 and Expression Analysis of YL-1
For RT-PCR of YL-1, we performed the same procedure
as described in Cox and Zoghbi (2000). Exceptions were
the RNA source, human heart poly (A)+ RNA, (Clontech,
6533–1), primers were YL1-35, GTAGGCGGTAT-
GAGTTTG, and YL1-1277, AAAACACAACGAAACCTG,
respectively, and the annealing temperature was 53°C.
The resulting RT-PCR product was subcloned using TA
cloning into pbluescript KSII+. This product was then se-
quenced to confirm that it matched the reported cDNA.
We examined the expression pattern of YL-1 using this
RT-PCR product as a probe on a Clontech Human multi-
ple tissue Northern blot (CAT# #7760–1).
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